natgillin/translations-raw huggingface dataset:
within 14 days of stopping these medicines. 
Zdravila DUROGESIC ne smete jemati še 14 dni po prenehanju jemanja teh zdravil.
The analgesic effect of the first dose of DUROGESIC patches will not be optimal within the first 24 hours. 
Analgetični učinek prvega odmerka transdermalnega obliža DUROGESIC v prvih 24 urah ne bo optimalen, zato mora bolnik prvih 12 ur po prehodu na transdermalni obliž DUROGESIC še vedno dobivati predhodne analgetike v enakem odmerku kot prej.
• Fits (seizures). 
• Napadi krčev (epileptični krči).
Convert this amount to the equianalgesic 24-hour oral morphine dose using the multiplication factors in Table 1 for the appropriate route of administration. 
Dobljeno vrednost pretvorite v odgovarjajočo 24-urno vrednost za peroralno uporabo morfina.
Application site reaction, Influenzalike illness, Feeling of body temperature change, 
občutek spremenjene telesne temperature,
Step 4: Disposing of the patch 
3. korak: Odstranite zaščitno folijo in pritisnite
A new patch should be applied to a different skin site after removal of the previous transdermal patch. 
Po odstranitvi starega transdermalnega obliža novega prilepimo na drugo mesto.
BATCH NUMBER 
ŠTEVILKA SERIJE Št. serije:
• DUROGESIC may cause constipation, talk to your doctor or pharmacist for advice on how to prevent or relieve constipation. 
Zdravnika ali farmacevta vprašajte za nasvet, kako preprečiti ali lajšati zaprtje.
Tolerance, physical dependence, and psychological dependence may develop upon repeated administration of opioids. 
Po večkratni uporabi opioidov se lahko pojavi toleranca ter telesna in duševna odvisnost.
Table 4: Recommended DUROGESIC dosage for paediatric patients1 based upon daily oral morphine dose2 
Preglednica 4: Priporočeni odmerek zdravila DUROGESIC pri pediatričnih bolnikih1, glede na dnevni peroralni odmerek morfina2 Peroralni 24-urni odmerek morfina (mg/dan)
What DUROGESIC is and what it is used for 
Kaj je zdravilo DUROGESIC in za kaj ga uporabljamo Vaše zdravilo se imenuje DUROGESIC.
Caution is advised upon concomitant use of CYP3A4 inducers and DUROGESIC. 
Pri sočasni uporabi induktorjev CYP3A4
• Being short of breath (dyspnoea) 
• zadihanost (dispneja)
If patients with hepatic impairment receive DUROGESIC, they should be observed carefully for signs of fentanyl toxicity and the dose of DUROGESIC reduced if necessary (see section 
Če bolniki z okvaro jeter prejemajo zdravilo DUROGESIC, jih je treba skrbno spremljati glede znakov toksičnih učinkov fentanila in jim odmerek zdravila DUROGESIC po potrebi zmanjšati (glejte poglavje 5.2).
Side effects and DUROGESIC 
Neželeni učinki in zdravilo DUROGESIC
DUROGESIC should not be administered to opioid-naïve paediatric patients (see section 4.2). 
Zdravila DUROGESIC ne smete uporabljati pri otrocih, ki še niso prejemali opioidov (glejte poglavje 4.2).
Centrally-acting medicinal products and alcohol 
Imetnik dovoljenja za promet z zdravilom in izdelovalec
Anaphylactic shock, 
Psihiatrične motnje nespečnost,
Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (eg, hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhoea). 
halucinacije, komo), avtonomno nestabilnost (npr. tahikardijo, spremenljiv krvni tlak, hipertermijo),
Skin does not appear to metabolise fentanyl delivered transdermally. 
Transdermalno vnešeni fentanil se v koži ne presnavlja.
6.5 Nature and contents of container [To be completed nationally] 
6.5 Vrsta ovojnine in vsebina
Generally, a patient should wait for 2 days after stopping treatment with a CYP3A4 inhibitor before applying the first DUROGESIC patch. 
šele 2 dni po prekinitvi zdravljenja z zaviralci CYP3A4.
STATEMENT OF ACTIVE SUBSTANCE(S) [To be completed nationally] 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN [izpolni država članica]
You should check with your doctor or pharmacist if you are not sure. 
posvetujte z zdravnikom ali farmacevtom.
Fatigue, Oedema peripheral, Asthenia, Malaise, Feeling cold 
Bolezni živčevja somnolenca, omotica, glavobol tremor, parestezija hipestezija, konvulzije
Bradypnoea 
OVOJNINAH
Therefore, they must keep all patches out of the sight and reach of children, both before and after use. 
Zato je treba vse obliže (neuporabljene in uporabljene) shranjevati nedosegljivo otrokom.
• If you get side effects talk to your doctor, pharmacist or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
DUROGESIC contains {name the excipient(s) 
DUROGESIC ali morfin).
Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. 
Če niste prepričani ali je med uporabo tega zdravila varno voziti, se o tem pogovorite z zdravnikom ali farmacevtom.
• Keep this leaflet. 
Upoštevajte zgornji nasvet.
Nausea, Vomiting, Constipation 
(npr. navzeo, bruhanje, drisko).
DUROGESIC can affect your ability to drive and use machines or tools as it may make you sleepy or dizzy. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo DUROGESIC lahko vpliva na sposobnost upravljanja vozil in strojev.
Date of first authorization: 15 June 2017 
Datum prve odobritve: 15 junij 2017
This may be months from now. 
To je lahko šele čez nekaj mesecev.
− CI = confidence interval. 
- IZ = interval zaupanja.
Why have I been given this card? 
Zakaj ste prejeli to kartico?
Each cycle has a duration of 28 days. 
Dolžina vsakega cikla je 28 dni.
If you feel dizzy, do not drive or use any tools or machines. 
Če ste omotični, ne vozite ali ne uporabljajte nobenih orodij ali strojev.
95.1%b CI (-3.2%, 24.3%)a 
95,1 %b IZ (−3,2 %, 24,3 %)a
It is important that you keep this Alert Card and show it to your partner or caregiver. 
Pomembno je, da to kartico hranite pri sebi in da jo pokažete svojemu partnerju ali skrbniku.
This is usually given every 3 week up to 8 times. 
Ta se po navadi daje na 3 tedne, do osemkrat.
Date of most recent infusion: __________ Date of first infusion: ________________ Patient's Name:_____________________ Doctor's Name:_____________________ Doctor's contact details:______________ 
Datum zadnjega infundiranja:____________ Datum prvega infundiranja:______________ Bolnikovo ime: _______________________ Zdravnikovo ime:______________________ Zdravnikov telefon:____________________
Some infections may be severe (please see information on Infections within this section). 
Nekatere okužbe so lahko hude (prosimo glejte informacije pod naslovom Okužbe v tem poglavju).
• Changes in laboratory tests carried out by your doctor. 
• spremembe rezultatov laboratorijskih preiskav, ki jih naroči vaš zdravnik.
It is important to check the medicinal product labels to ensure that the appropriate formulation is being given to the patient, as prescribed. 
Pomembno je preveriti nalepke na zdravilu in tako zagotoviti, da bolnik dobi ustrezno obliko, ki mu je bila predpisana.
− * Worst case imputation a Non-inferiority was demonstrated since the lower bound (− 3.2%) was higher than the predetermined non-inferiority margin (− 20%). 
- * Imputacija za najslabši primer a Neinferiornost je bila dokazana, ker je bila spodnja meja (−3,2 %) višja od vnaprej opredeljene meje neinferiornosti (−20 %).
The prespecified non-inferiority margin for the treatment difference was 20%. 
Vnaprej opredeljena meja neinferiornosti za razliko zdravljenj je bila 20 %.
• a reduction in white blood cells which does not happen straight away 
• zmanjšanje števila belih krvnih celic, ki se ne pojavi takoj,
As the Patient Alert Card is part of the product information in the outer packaging, the content will be centrally approved for all EU/EEA languages without need of further approval by National Authorities. 
Ker je opozorilna kartica za bolnika del povzetka glavnih značilnosti zdravila v zunanjem pakiranju, bo njena vsebina centralno odobrena za vse jezike EU/EGS, pri čemer dodatna odobritev s strani nacionalnih organov ni potrebna.
The incidence of serious infections was similar in both arms (approximately 12%). 
Pojavnost resnih okužb je bila v obeh skupinah podobna (približno 12 %).
Alternative subsequent, faster, infusion schedule 
Alternativna nadaljnja, hitrejša infuzija
The risk of disease progression was reduced by 46% and the risk of relapse by 51%. 
Tveganje za napredovanje bolezni je bilo manjše za 46 %, tveganje za ponovitev bolezni pa za 51 %.
All IRRs were CTC Grade 1 or 2. 
IRR so bile 1. ali 2. stopnje po CTC.
Do not have Rixathon if you have an active infection or a serious problem with your immune system. 
Zdravila Rixathon ne smete prejeti, če imate aktivno okužbo ali resno težavo s svojim imunskim sistemom.
• you have a weak immune system. 
• imate oslabel imunski sistem;
Both tests are commonly positive in rheumatoid arthritis and aid in confirming the diagnosis. 
Oba testa sta pri revmatoidnem artritisu običajno pozitivna in pomagata pri potrditvi diagnoze.
Do not use this medicine after the expiry date which is stated on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »EXP«.
Your doctor will decide if you should receive concomitant supportive therapy. 
Zdravnik se bo odločil, ali boste sočasno prejeli tudi podporno zdravljenje.
• high or low blood pressure (low blood pressure especially when standing upright) 
• visok ali nizek krvni tlak (nizek krvni tlak zlasti po hitrem vstajanju),
Preparation should be: - performed under aseptic conditions by trained personnel in accordance with good practice rules especially with respect to the aseptic preparation of parenteral products. 
Zdravilo mora: - pripraviti usposobljeno osebje v aseptičnih pogojih v skladu s pravili dobre prakse, še zlasti glede aseptične priprave parenteralnih zdravil
Available data suggest that clinical response is usually achieved within 16 to 24 weeks of an initial treatment course. 
Podatki, ki so na voljo, kažejo, da je klinični odziv ponavadi dosežen v roku 16-24 tednov po začetnem ciklu zdravljenja.
Binet stage A Binet stage B Binet stage C CI: Confidence Interval 
stopnja po Binetu A stopnja po Binetu B stopnja po Binetu C IZ: interval zaupanja
Patients should receive Rixathon for at least 24 months after achievement of remission (absence of clinical signs and symptoms). 
Rixathon prejemati vsaj 24 mesecev po doseženi remisiji (odsotnost kliničnih znakov in simptomov).
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če je ne uporabimo takoj, je za čas in pogoje shranjevanja pred uporabo odgovoren uporabnik; čas običajno ne sme presegati 24 ur pri temperaturi od 2 °C do 8 °C, razen če je bila raztopina pripravljena v nadzorovanih in validiranih aseptičnih pogojih.
Premedication and prophylactic medications 
Premedikacija in profilaktična zdravila
• long lasting depression 
• dolgotrajna depresija,
These include a decrease in the amount of some specific proteins in the blood (immunoglobulins) which help protect against infection. 
Te vključujejo zmanjšanje količine nekaterih specifičnih beljakovin v krvi (imunoglobulinov), ki pomagajo varovati pred okužbami.
Your doctor may decide to treat you longer with Rixathon (up to 5 years), depending on how you respond to the medicine. 
Zdravnik se lahko odloči, da vas bo z zdravilom Rixathon zdravil dlje (do 5 let), odvisno od tega, kako se odzovete na zdravilo.
Table 14 Physical Function and Quality of Life outcomes at week 24 in Trial 1 
Funkcijska zmogljivost in vpliv na kakovost življenja po 24 tednih v preskušanju 1
Of 356 patients evaluated for anti-drug antibody (ADA), 1.1% (4 patients) were positive. 
Od 356 bolnikov, pri katerih so ocenjevali prisotnost protiteles proti zdravilu (anti-drug antibody - ADA), so bili pozitivni 4 bolniki (1,1 %).
• asthma, too little oxygen reaching the body organs 
• astma, telesne organe doseže premalo kisika,
Percent age of Patients with First Major Relapse 
Odstotek bolnikov s prvim hujšim recidivom
* at end of maintenance/observation; final analysis results based on median follow-up of 73 months. 
* ob koncu vzdrževalnega zdravljenja/spremljanja; rezultati končne analize temeljijo na mediani spremljanja
• Show this card to any doctor, nurse or dentist you see - not just the specialist who prescribes your Rixathon. 
• Pokažite jo vsem zdravnikom, medicinskim sestram in zobozdravnikom, ki jih obiščete - ne samo specialistu, ki vam predpiše zdravilo Rixathon.
Complete remission All patients Newly diagnosed Relapsing 
Popolna remisija Vsi bolniki Novoodkriti Ponovitev
Rituximab was detectable in the serum of patients 3 to 6 months after completion of last treatment. 
Rituksimab je bilo mogoče zaznati v serumu bolnikov 3 do 6 mesecev po zaključku zadnjega zdravljenja.
The need for further courses should be evaluated 24 weeks following the previous course. 
Potrebo po nadaljnjih ciklih zdravljenja je treba oceniti 24 tednov po predhodnem ciklu.
Your doctor may decide to stop your Rixathon treatment if these reactions are serious. 
Zdravnik se lahko odloči za prenehanje zdravljenja z zdravilom Rixathon, če so te reakcije resne.
Rixathon will be given to you by a doctor or nurse who is experienced in the use of this treatment. 
Zdravilo Rixathon vam bo dal zdravnik ali medicinska sestra, ki ima izkušnje z uporabo takšnih zdravil.
Rixathon may also cause changes in laboratory tests carried out by your doctor. 
Zdravilo Rixathon lahko vpliva tudi na spremembe laboratorijskih preiskav, ki jih naroči vaš zdravnik.
• mood disorders such as irritability and depression 
• spremembe razpoloženja, kot sta razdražljivost in depresija,
It remains unknown if early detection of PML and suspension of rituximab therapy may lead to similar stabilisation or improved outcome. 
Ni znano, ali lahko zgodnje odkritje PML in ukinitev zdravljenja z rituksimabom doseže podobno stabilizacijo ali izboljšanje izida.
The safety and efficacy of rituximab in children below 18 years have not been established. 
Varnost in učinkovitost rituksimaba pri otrocih do 18. leta starosti nista dokazani.
• Excess fluid retention in the face and body 
• zadrževanje odvečne tekočine v obrazu in telesu,
Patients were followed beyond week 24 for long term endpoints, including radiographic assessment at 56 weeks and at 104 weeks. 
Bolnike so od 24. tedna spremljali za dolgoročne cilje študije in naredili tudi radiološko oceno po 56 tednih ter 104 tednih.
Population pharmacokinetic analysis of the same data gave similar mean values for systemic clearance and half-life, 0.26 L/day and 20.4 days, respectively. 
Populacijska farmakokinetična analiza istih podatkov je dala podobne povprečne vrednosti za sistemski očistek in razpolovni čas, 0,26 l/dan in 20,4 dni.
• ringing sound in the ears, ear pain 
• zvonjenje v ušesih, bolečine v ušesu,
If you can get pregnant, you and your partner must use an effective method of contraception while using Rixathon. 
Če bi lahko zanosili, morate vi in vaš partner med uporabo zdravila Rixathon uporabljati učinkovito kontracepcijsko zaščito.
• reduced platelets number just after the infusion - this can be reversed, but can be fatal in rare cases 
• zmanjšanje števila trombocitov tik po infundiranju zdravila - to je mogoče odpraviti, a v redkih primerih je lahko smrtno,
Retreatment should be given at that time if residual disease activity remains, otherwise retreatment should be delayed until disease activity returns. 
Ob tem času je treba bolnika ponovno zdraviti, če je bolezen še vedno aktivna, sicer pa se ponovno zdravljenje odloži, dokler bolezen spet ne postane aktivna.
1 Events were considered ADRs only after thorough assessment and where a causal relationship between the medicinal product and the adverse event was at least a reasonable possibility. 
1 Dogodke so kot neželene učinke ocenili šele po natančni oceni in v primerih, v katerih je bila vzročna povezanost med zdravilom in neželenim učinkom vsaj smiselna možnost.
The transient IgM increase usually returned to at least baseline level within 4 months. 
Prehodna zvišanja IgM so se običajno vrnila vsaj na raven pred zdravljenjem v 4 mesecih.
• Cardiovascular events, see section 4.4. 
• kardiovaskularni dogodki, glejte poglavje 4.4.
Tell your doctor immediately if you experience any of these symptoms. 
Nemudoma povejte zdravniku, če se pri vas pojavi kateri od teh simptomov.
All patients Newly diagnosed Relapsing n=99 n=48 n=51 
Vsi bolniki Novoodkriti Ponovitev n = 99 n = 48 n = 51
2Details on infusion related reactions are provided in the description of selected adverse drug reactions section. 
2 Podrobnosti o reakcijah, povezanih z infundiranjem, so navedene v opisu v poglavju o izbranih neželenih učinkih zdravila.
The incidence of IRR symptoms was highest during or after the first infusion (9%) and decreased with subsequent infusions (<4%). 
Pojavnost simptomov IRR je bila največja med prvo infuzijo ali po njej (9 %) in se je ob nadaljnjih infuzijah zmanjšala (< 4 %).
Aseptic handling must be ensured when preparing the infusion. 
Pri pripravi infuzije je treba zagotoviti aseptično rokovanje.
Severe infusion-related reactions (such as bronchospasm, hypotension) occurred in up to 12% of the cases. 
Hude reakcije, povezane z infuzijo (npr. bronhospazem, hipotenzija), so se pojavile pri do 12 % bolnikov.
Rixathon in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes. 
Zdravilo Rixathon v kombinaciji s kemoterapijo uniči te celice, ki se postopno odstranijo iz telesa z biološkimi procesi.
The proliferation of these abnormal B-lymphocytes is the cause of symptoms you may have. 
Nastajanje teh nenormalnih limfocitov B je vzrok simptomom, ki jih morda imate.
Depending on the signs and symptoms of your disease, your doctor will decide when you should receive more Rixathon. 
Glede na znake in simptome vaše bolezni se bo zdravnik odločil, kdaj boste ponovno zdravljeni z zdravilom Rixathon.
- prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents. 
- biti pripravljeno v komori z laminarnim pretokom zraka ali v biološki varnostni komori, z uporabo standardnih previdnostnih ukrepov za varno ravnanje z intravenskimi zdravili.
Very Rare Not known 
Zelo redki Neznana
Patients reporting signs and symptoms of infection following Rixathon therapy should be promptly evaluated and treated appropriately. 
Bolnike, pri katerih se pojavijo znaki in simptomi okužbe po zdravljenju z zdravilom Rixathon, je treba nemudoma pregledati in primerno zdraviti.
The HCP educational leaflets and the Patient educational leaflet will be agreed with the National Competent Authorities prior to distribution. 
O izobraževalnih letakih za zdravstvenega delavca in izobraževalnih letakih za bolnika bo pred razdelitvijo dogovorjeno z nacionalnim organom, pristojnim za zdravila.
EULAR response (%) 
Odziv po EULAR (%)
• low mood and loss of interest or enjoyment in doing things, feeling nervous 
• slabo razpoloženje in izguba zanimanja ali veselja za početje stvari, živčnost,
Therefore patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely. 
Zato je treba bolnike z anamnezo srčne bolezni in/ali kardiotoksične kemoterapije skrbno nadzorovati.
6336 Langkampfen Austria 
6336 Langkampfen AVSTRIJA
6336 Langkampfen AUSTRIA 
6336 Langkampfen Avstrija
Following reconstitution of the immune system in immunocompromised patients with PML, stabilisation or improved outcome has been seen. 
Po okrevanju imunskega sistema pri imunsko oslabljenih bolnikih s PML so opazili stabilizacijo ali izboljšanje izida.
The incidence of infections that were serious or required intravenous antibiotics was approximately 4 per 100 patient years. 
Incidenca okužb, ki so bile resne ali so zahtevale uporabo intravenskega antibiotika, je bila približno 4 na 100 bolnik-let.
The most frequently reported events were tachycardia (4%) and atrial fibrillation (3%) (see section 4.4). 
Najpogosteje opisana neželena učinka sta bila tahikardija (4 %) in atrijska fibrilacija (3 %) (glejte poglavje 4.4).
The alert card contains important safety information for patients regarding potential increased risk of infections, including progressive multifocal leukoencephalopathy (PML). 
Opozorilna kartica vsebuje za bolnika pomembne podatke o varnosti glede možnega povečanega tveganja za okužbe, vključno s progresivno multifokalno levkoencefalopatijo (PML).
Before you are given Rixathon you will be given other medicines (premedication) to prevent or reduce possible side effects. 
Preden boste dobili zdravilo Rixathon, boste dobili druga zdravila (to imenujemo premedikacija) za preprečitev ali zmanjšanje možnih neželenih učinkov.
• tremors (shakiness, often in the hands) 
• tremor (tresenje, pogosto tresenje rok),
• painful joints or back 
• boleči sklepi ali hrbet,
38 months 
38 mesecev NR
Rarely Rixathon can cause a serious brain infection, called “Progressive Multifocal Leukoencephalopathy” or PML. 
Redko lahko zdravilo Rixathon povzroči resno možgansko okužbo, imenovano progresivna multifokalna levkoencefalopatija ali PML.
For these reasons Rixathon should not be administered to pregnant women unless the possible benefit outweighs the potential risk. 
Zato nosečnice ne smejo prejemati zdravila Rixathon, razen če je pričakovana korist večja od možnega tveganja.
Prednisone treatment was tapered and then kept at a low dose (approximately 5 mg per day) for at least 18 months after randomization. 
Zdravljenje s prednizonom so postopoma zmanjšali in ga nato vzdrževali v majhnem odmerku (približno 5 mg na dan) vsaj 18 mesecev po randomizaciji.
In clinical trials more than 3,100 patients received at least one treatment course and were followed for periods ranging from 6 months to over 5 years; approximately 2,400 patients received two or more courses of treatment with over 1,000 having received 5 or more courses. 
V kliničnih preskušanjih je več kot 3.100 bolnikov prejelo najmanj en cikel zdravljenja, po tem so jih spremljali od 6 mesecev do več kot 5 let; približno 2.400 bolnikov je prejelo dva ali več ciklov zdravljenja, od teh pa več kot 1.000 bolnikov 5 ali več ciklov zdravljenja.
Observation N=513 
Opazovanje n = 513
p-value Risk reduction1) 
R-CHOP Vrednost p Zmanjšanje tveganja1)
You may be asked not to take these other medicines 12 hours before you are given Rixathon. 
Morda vam bo naročil, da ne jemljite teh drugih zdravil 12 ur, preden boste dobili zdravilo Rixathon.
1 Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials 
1Pogostnost pridobljena iz laboratorijskih vrednosti zbranih v okviru rutinskega laboratorijskega spremljanja v kliničnih preskušanjih.
Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146) 
Slika 2: Odzivi ACR za 4 cikle zdravljenja 24 tednov po vsakem ciklu (intraindividualno, znotraj pregledov) pri bolnikih, ki niso zadostno odgovorili na zdravljenje z zaviralci TNF (n = 146)
Long-term efficacy with multiple course therapy 
Dolgotrajna učinkovitost z več cikli zdravljenja
CD20 is found on both normal and malignant B cells, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissue. 
CD20 najdemo tako na običajnih kot na malignih celicah B, vendar ne na matičnih krvotvornih celicah, pro-B-celicah, normalnih plazmatkah ali drugem normalnem tkivu.
Vaccination should be completed at least 4 weeks prior to first administration of Rixathon. 
Cepljenje naj bo zaključeno najmanj 4 tedne pred prvo aplikacijo zdravila Rixathon.
In contrast, three patients (1.5%) had cerebrovascular events in the CHOP group, all of which occurred during the follow-up period. 
Nasprotno pa so se cerebrovaskularni dogodki pojavili pri treh bolnikih (1,5 %) v skupini CHOP, vsi med obdobjem spremljanja.